tirzepatide prior authorization Aetna for Zepbound Guidance for prior authorization and

Meaningful weight loss typically becomes visible by weeks four to six

Stay in touch with your healthcare team

Many patients begin to notice improvements in cognitive function within a few weeks of starting Dihexa treatment

For the treatment-regimen estimandiii, results showed: Average body weight reductions: 12.8% (10mg), 14.7% (15mg), 3.2% (placebo) Percentage of participants achieving body weight reductions of 5%: 79.2% (10mg), 82.7% (15mg), 32.5% (placebo) Percentage of participants achieving body weight reductions of 15%: 39.7% (10mg), 48.0% (15mg), 2.7% (placebo) The overall safety profile of tirzepatide was similar to previously reported SURMOUNT and SURPASS trials and to incretin-based therapies approved for the treatment of obesity and overweight